Virulence

Laboratory Testing and PCR Technology Lead the India Infectious Disease Diagnostics Market, Transforming Disease Detection and Management - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023

The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.

Key Points: 
  • The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.
  • The India emerging infectious disease diagnostics market is currently in an emerging phase.
  • The India emerging infectious disease diagnostics market plays a pivotal role in modern biotechnology, clinical diagnostics, and pathogen research.
  • The India emerging infectious disease diagnostics market is segmented into key categories:
    In FY2022, laboratory testing was the dominant application segment in the India emerging infectious disease diagnostics market.

Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study

Retrieved on: 
Thursday, November 2, 2023

The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.

Key Points: 
  • The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.
  • Once a human is infected, Ebola virus disease can be lethal within 4-5 days.
  • Maxwell is currently developing its Claromer drug platform, which has the potential to replace almost all antibiotics, antifungals and antivirals.
  • Since the first outbreak in Africa in 1976, several outbreaks and epidemics of Ebola virus have occurred in Western and Central Africa.

MEDGENE'S RHDV2 VACCINE GRANTED CRITICAL LICENSE BY USDA'S CENTER FOR VETERINARY BIOLOGICS

Retrieved on: 
Thursday, November 2, 2023

BROOKINGS, S.D., Nov. 2, 2023 /PRNewswire/ -- Medgene, an animal health company that produces highly-targeted platform vaccines, has been granted a Conditional Use License by the United States Department of Agriculture's Center for Veterinary Biologics (USDA-CVB) to further manufacture and distribute its vaccine targeted at Rabbit Hemorrhagic Disease (RHDV2).

Key Points: 
  • BROOKINGS, S.D., Nov. 2, 2023 /PRNewswire/ -- Medgene, an animal health company that produces highly-targeted platform vaccines, has been granted a Conditional Use License by the United States Department of Agriculture's Center for Veterinary Biologics (USDA-CVB) to further manufacture and distribute its vaccine targeted at Rabbit Hemorrhagic Disease (RHDV2).
  • Once contracted, RHDV2 is usually fatal and affects wild and domestic rabbit populations.
  • Medgene's Conditional Use License is especially important for designated State Veterinarians as they are the authority allowing distribution of the vaccine within their respective states.
  • Rabbit owners are encouraged to contact their local veterinarian for more information on RHDV2 and vaccination.

World Emerging Infectious Disease Diagnostics Market Research Report 2023: Respiratory Infections Take Center Stage in Infectious Disease Diagnostics Post-COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 25, 2023

The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.

Key Points: 
  • The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.
  • North America, encompassing both the United States and Canada, currently holds the largest share in the global emerging infectious disease diagnostics market.
  • Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.
  • Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing.

A MIXTURE OF LANGUAGES TO INTERPRET TODAY'S CHALLENGES: INTERNATIONAL ARTISTS AND LOCAL TALENTS ON SHOW IN BERGAMO AND BRESCIA, ITALIAN CAPITAL OF CULTURE 2023

Retrieved on: 
Wednesday, October 25, 2023

BERGAMO and BRESCIA, Italy, Oct. 25, 2023 /PRNewswire/ -- Digital languages, installations, art exhibitions and photography: though various languages, the Italian Capital of Culture 2023 interprets today's changing reality from an unusual perspective, involving great international artists and local talents in Bergamo and Brescia.

Key Points: 
  • BERGAMO and BRESCIA, Italy, Oct. 25, 2023 /PRNewswire/ -- Digital languages, installations, art exhibitions and photography: though various languages, the Italian Capital of Culture 2023 interprets today's changing reality from an unusual perspective, involving great international artists and local talents in Bergamo and Brescia.
  • Lebanese visual artist Ali Cherri is staging his largest solo exhibition ever with film, video installations, drawings and sculptures at GAMec (Bergamo until 14 January).
  • Fifty artists from Brescia and Bergamo feature in "Presente Inquieto" (Bergamo until 12 November) transforming industrial tradition into an artistic interpretation of the needs of their communities.
  • Institutional partners: Ministry of Culture, the Lombardy Region, Fondazione Cariplo, Fondazione della Comunità Bresciana and Fondazione della Comunità Bergamasca.

Great Expectations: new theatrical adaptation sets Dickens novel in partition-era Bengal

Retrieved on: 
Monday, October 2, 2023

The vision of the boy in front of the ruins of his family is one of rude survivalism.

Key Points: 
  • The vision of the boy in front of the ruins of his family is one of rude survivalism.
  • It’s a trait that will see Pip through the misadventures ahead – but the sorrow of surviving on these terms is unmistakable.
  • However, Tanika Gupta’s adaptation of Great Expectations, currently showing at Manchester’s Royal Exchange Theatre, opens with “Pipli” buzzing around, doing cartwheels, at ease in his world.
  • Dickens brought the upper classes to their knees in his novels, exposing the entanglements of gentility and criminality.

Pip and Magwitch

    • In the Dickens novel, Pip refuses to treat his terrifying encounter with Magwitch as anything other than a “chance occurrence”.
    • Magwitch – who reinvents himself in the penal colony of Australia, where he is transported to – becomes the anonymous benefactor whose colonial labour finances Pip’s education.
    • Dickens’s Pip does not treat his entry into Satis House – the estate of Miss Havisham – as the random event it is.

MacCaulay’s Minute

    • In Gupta’s play, the backdrop to Pipli’s soul-searching is the first partition of Bengal into East and West Bengal (1905).
    • This echoes politician Thomas Babington Macaulay’s Minute Upon Indian Education (1835), which shaped British educational policy.
    • The Macaulay Minute ushered a colonial modernity no longer reliant on the indigenous literature and culture and bred mimic men fully compliant with British rule.

The language issue

    • The treatment of language in decolonising Dickens’s Great Expectations is a missed opportunity.
    • Furthermore, little attention is paid to differences between Bengali Hindus and Muslims when it came to their respective reckonings of Curzon’s division.
    • This is clever, but reinforces once again the power of English to stand in as both global language and local vernacular.

Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Retrieved on: 
Monday, September 11, 2023

WOODCLIFF LAKE, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its abstract describing the global in-progress Phase 2 study of CAL02, a first-in-class, broad-spectrum, anti-virulence agent under development as an adjunct to antibiotic therapy for the treatment of severe community-acquired bacterial pneumonia (“SCABP”), has been selected for a poster presentation at the conference co-sponsored by the American Society for Microbiology (“ASM”) and the European Society for Clinical Microbiology and Infectious Diseases (“ESCMID”). This prestigious, multidisciplinary meeting is focused on the challenges, opportunities, and current requirements for antimicrobial drug development to address antimicrobial resistance. The conference is scheduled to take place September 19-22, 2023, in Boston, Massachusetts.

Key Points: 
  • This prestigious, multidisciplinary meeting is focused on the challenges, opportunities, and current requirements for antimicrobial drug development to address antimicrobial resistance.
  • The conference is scheduled to take place September 19-22, 2023, in Boston, Massachusetts.
  • “We are pleased to have the opportunity to present additional details of the CAL02 study in progress to our esteemed colleagues,” stated Valentin Curt, MD, Senior Vice President, Clinical Drug Development and Interim Chief Medical Officer at Eagle Pharmaceuticals.
  • “Inclusion at this scientific congress supports the significance of the potential clinical value of CAL02 to address a large, unmet medical need.

The WHO has declared Eris a 'variant of interest'. How is it different from other Omicron variants?

Retrieved on: 
Thursday, August 10, 2023

EG.5 is a family of Omicron variants (descended from XBB.1.9.2) that first appeared back in February 2023.

Key Points: 
  • EG.5 is a family of Omicron variants (descended from XBB.1.9.2) that first appeared back in February 2023.
  • The World Health Organization (WHO) classified it as a “variant under monitoring” on July 19 after a surge in COVID infections from early July.
  • Eris has seen EG.5 jump from 7.6% of all SARS-CoV-2 genetically sequenced globally in late June, to 17.4% in the week of July 17-23.
  • Eris has edged out other Omicron variants circulating in the United States, and now makes up the largest proportion of COVID cases there.

Is Eris different to other variants?

    • How this virus enters cells and tissues in our body is also similar to XBB.1.5 (sometimes referred to as Kraken) and other Omicron variants.
    • While the severity of the illness it causes will need to be documented carefully, there are no indications it’s different from XBB.1.5.
    • While this enables it to compete with other circulating variants, it’s unclear if or when Eris will out-compete other variants in Australia.

What variants is the WHO watching?

    • The current variant of interest list also includes two other Omicron cousins – XBB 1.5 and XBB 1.16 (the latter sometimes referred to as Arcturus).
    • Read more:
      When is a COVID mutation a new variant, and when is it a subvariant?
    • How closely related the new variant is to the variants already circulating in the population is another key factor.

Will vaccines protect against it?

    • EG.5.1 has two important additional mutations that XBB.1.9.2 does not have: F456L and Q52H, whereas EG.5 only has F456L.
    • The extra small change in EG.5.1, the Q52H mutation in the spike protein, is enough to give EG.5.1 an edge over EG.5 in transmissibility.
    • The good news is the bivalent vaccine antibody responses to EG.5.1 are similar to those for variants that dominated earlier in the year in Australia.
    • We found that while the antibody response wanes the longer it has been since the last vaccine dose or infection, this is not at levels significantly different to XBB.1.5.
    • Importantly, bivalent vaccine doses, such as Moderna’s BA.1 bivalent booster, generate a five-fold increase in antibodies that protect against variants in circulation, including EG.5.1.

Will Eris prompt a rise in COVID cases?

    • By August 7 2023, there had been 158 known cases reported via whole genome sequencing across Australia, representing 2.1% of reported variants.
    • Encouragingly, Australia’s overall infection rates continue to decline, as do hospitalisations and COVID-related deaths, antiviral scripts, and reports of cases in aged care.
    • Read more:
      Do I need a booster vaccine if I recently had COVID?
    • India first saw this variant back in May, but it has also seen only sporadic cases, and no major rise in overall infections.

COVID is becoming less of a threat but still needs watching

    • It’s also heartening that emerging variants aren’t genetically that different, so our immunity, vaccines, testing and treatment are still effective in protecting us from serious illness.
    • The more time our immune systems have to mature, the more they can respond to a range variants far better than before.
    • Our antibodies may wane over time, but the pool that are left represent quality rather than quantity in their ability to target many variants.

Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)

Retrieved on: 
Monday, July 24, 2023

The Phase 2 study plans to enroll approximately 276 patients with SCABP at more than 100 sites in over 20 countries worldwide.

Key Points: 
  • The Phase 2 study plans to enroll approximately 276 patients with SCABP at more than 100 sites in over 20 countries worldwide.
  • In addition, depending upon recruitment rates, Eagle anticipates having its first 50% interim report around the first quarter of 2024.
  • CAL02 is a novel first-in-class broad-spectrum anti-virulence agent being developed as an add-on to standard of care treatment of SCABP.
  • In August 2021, Eagle entered into a worldwide licensing agreement with Combioxin SA for the commercial rights to CAL02.

CHOP Researchers Reveal How NSAIDs Worsen C. difficile Infections

Retrieved on: 
Wednesday, July 19, 2023

PHILADELPHIA, July 19, 2023 /PRNewswire/ -- Why do nonsteroidal anti-inflammatory drugs (NSAIDs) exacerbate gastrointestinal infections by Clostridioides difficile, the leading cause of antibiotic-associated diarrhea worldwide? In a new paper published in Science Advances, researchers at Children's Hospital of Philadelphia (CHOP) have begun to answer that question, showing that NSAIDs disrupt the mitochondria of cells lining the colon, sensitizing them to damage by pathogenic toxins.

Key Points: 
  • However, researchers still know very little about how these factors impact the course of C. difficile infection.
  • Prior studies have shown that NSAIDs like indomethacin, aspirin, and naproxen negatively affect the gut, both in patients with C. difficile infection and other conditions like inflammatory bowel disease (IBD).
  • The researchers observed that both indomethacin and a C. difficile toxins increased epithelial cell barrier permeability and inflammatory cell death.
  • Surprisingly, the researchers found that NSAIDs exacerbate C. difficile infection independent of COX inhibition and instead through off-target effects on mitochondria.